Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Changes in the College Mobility Pipeline Since 1900. Zachary Bleemer & Sarah Quincy. Share. X LinkedIn Facebook Bluesky Threads Email Link. Working Paper 33797 DOI 10.3386/w33797 Issue Date May 2025.

Figure 1.Overview of ICARus pipeline. (A) Pipeline diagram overview of ICARus.(B) The input for ICARus is a (Genes x Samples) normalized gene expression matrix where the rows are gene symbols (IDs) ...

Biogen has initiated the BRAVE study, a global Phase 3 clinical trial to evaluate omaveloxolone in children with Friedreich ataxia, addressing a critical unmet need in the pediatric population.

And when we take into account its pipeline and the recent deals it's made, Novo Nordisk looks even more promising -- the weight-management market is on an incredible growth path.

There was never any doubt she supported the Summit pipeline. But she had the Iowa Senate do her dirty work blocking past legislation. A bill finally broke through the Senate and made it to her desk.

Biogen Safe Harbor This news release ... the treatment of Friedreich’s ataxia; the potential of Biogen’s commercial business and pipeline programs, including Friedreich’s ataxia; ...

This news release contains forward-looking statements including relating to the potential benefits, safety and efficacy of SKYCLARYS; potential regulatory discussions, submissions and approvals and ...

Biogen's BIIB short percent of float has risen 13.95% since its last report. The company recently reported that it has 3.80 million shares sold short, which is 3.35% of all regular shares that are ...

Biogen Inc. (NASDAQ:BIIB) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Biogen Inc.

With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making a comeback. After a lackluster showing in 2024 extended a yearslong ...